EMERGENT BIOSOLUTIONS INC (EBS)
Health Care · Biotechnology and CDMO Services · NYSE
Emergent BioSolutions is a specialized biopharmaceutical firm that provides critical medical countermeasures and manufacturing services to protect against global public health threats and opioid overdose emergencies.
What EMERGENT BIOSOLUTIONS INC does
Emergent BioSolutions is a global life sciences company that develops, manufactures, and delivers medical countermeasures and specialized pharmaceutical products to address public health threats. Its business is organized into three segments: Commercial Products (focused on opioid overdose reversal, including NARCAN Nasal Spray), Medical Countermeasure (MCM) Products (focused on vaccines and therapeutics for diseases like anthrax, smallpox, and Ebola), and a Services segment providing contract development and manufacturing (CDMO) services. The company serves government agencies and commercial markets with products designed to combat chemical, biological, radiological, nuclear, and explosive (CBRNE) threats and emerging infectious diseases.
Themes: Medical countermeasures / biodefense, Opioid overdose emergency response, CBRNE preparedness, Emerging infectious diseases / vaccines, Contract manufacturing / CDMO services, Government procurement
Fundamentals
- Price$5.18 as of 2026-08-24 close
- Market cap$266M as of 2026-08-24
- 1-year return-43.9% 2025-08-22 close $9.23 → 2026-08-24 close $5.18
- P/En/a negative earnings
- Net margin-1.3% as of 2026-08-24
- Gross margin+54.3% as of 2026-08-24
- ROE-1.6% as of 2026-08-24
- Debt / equity1.10 as of 2026-08-24
- Revenue growth (YoY)-29.9% as of 2026-08-24
- Revenue CAGR (3y)-12.7% SEC XBRL
- Beta1.62 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How EBS compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How EMERGENT BIOSOLUTIONS INC looks technically
EMERGENT BIOSOLUTIONS INC (EBS) is trading 45.4% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 91 trading days ago — a "death cross", a bearish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 46, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive). It made a new 20-day low about 9 trading days ago. It is 63.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 45.4% below its 200-day average, the long-term trend line — a long-term downtrend | -45.5% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $7.11 | $7.11 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $9.31 | $9.31 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 11 calendar days ago — the swings before that are what the structure reading is measured on | 11 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 7.58. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a completed three-part correction. | possible downward five-wave sequence, in wave 4 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 91 trading days ago — a "death cross", a bearish long-term signal | 91 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 46, with sellers in control | 46.1 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30) | 34.9 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($4.37 to $7.70) — its "stochastic" reading is 21 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 21.4 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 1 trading day ago (its momentum flipped positive) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $14.06 | $14.06 |
|---|---|---|
| From the 52-week high | it is 63.9% below its 52-week high (its highest price of the past year) | -63.9% |
| Above the 52-week low | it is 16.4% above its 52-week low (its lowest price of the past year) | +16.4% |
| Below the 52-week high | it is 63.9% below its highest point of the past year | 63.9% |
| Since a 20-day breakout | it made a new 20-day low about 9 trading days ago | 9 sessions |
| Since a 55-day breakout | it made a new 55-day low about 9 trading days ago | 9 sessions |
| All-time high | its highest closing price on record is $137.61 (set on 2020-08-06) | $137.61 |
| Given back of the 52-week move | over the past year its closes ranged ($4.45 to $13.90), and it has recovered only a small part of its fall from last year’s high — 7% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $10.29 to $10.59. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 6.7% |
| From the all-time high | it is 96.3% below its all-time high | -96.3% |
| Nearest price level | it is trading 11.6% below a resistance level at $5.67 — a price it turned at three times since 2024-09-25, most recently on 2025-08-04. Since 2024-08-21 it has 0 such levels below the current price and 17 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +11.6% |
| All-time low | its lowest closing price on record is $1.42 (set on 2024-02-06) | $1.42 |
| Above the all-time low | it is 257.7% above its all-time low | +257.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 98% of the past ~6 months) | 98th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.3645 between its high and its low — about 7.2% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.3645 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.15 and $8.42 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.15 – $5.78 – $8.42 |
| Typical daily range (% of price) | its price moves about 7.2% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.2% |
| Stretch from the 200-day average | it is trading 11.6 daily ranges below its 200-day average price (45.5% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 11.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.29× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 8.3% since the prior reading | -8.3% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a doji | 4 sessions ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.6% |
|---|---|---|
| Open gap | it gapped 21.1% below the previous close 11 sessions ago and has not traded back through the level it left behind at 7.54 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -21.1% |
| Gap filled | a 2.5% gap down opened on 2026-08-10 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it took 7 sessions to close | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 35.9 percentage points (the stock lost 33.6% while the market gained 2.3%) | -35.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 42.4 percentage points (the stock lost 39.3% while the market gained 3.1%) | -42.4% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 64.6 percentage points (the stock lost 53.5% while the market gained 11.1%) | -64.6% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 66.0 percentage points (the stock lost 45.5% while the market gained 20.5%) | -66.0% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bearish state: a strong downtrend, with sellers in control, a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 36% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 11.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -36.2% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 39% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $8.37 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -39.3% |
|---|---|---|
| Vs the average paid since it last reported | the price is 5% above the average price paid since it last reported on 2026-08-05 (its 8-K), so the typical buyer over that stretch is showing a gain. That average is $4.86 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +4.6% |
Price levels it has turned at before
EBS last closed at $5.08 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 17 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $5.67 | Resistance | 11.6% above the last close | turned there three times · 2024-09-25 to 2025-08-04 |
| $6.03 | Resistance | 18.6% above the last close | turned there twice · 2025-06-05 to 2025-06-18 |
| $6.17 | Resistance | 21.5% above the last close | turned there twice · 2025-05-27 to 2025-07-01 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $7.58.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $5.37 and $6.50 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a completed three-part correction, which fails on a close below $4.37.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · Analyst price target recently CUT · lagging the market · Printed a bullish engulfing pair | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 2 analysts
- Mean price target$11.00 range $10.00 – $12.00
Analyst estimates, as of 2026-08-19. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for EBS
- Consensus EPS estimate-$0.41 next reporting period, as of 2026-08-19
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Heavy dependence on U.S. government funding and contracts for MCM products (anthrax, smallpox, botulism vaccines/antivirals), with risk of contract non-renewal or procurement delays","Intense commercial competition and generic marketplace pressures on NARCAN® naloxone products; declining revenue (-29.89% YoY as of filing date) and current unprofitability","Regulatory compliance, manufacturing quality, and ability to meet government delivery specifications and timelines; pending government investigations noted"]
What changed in the latest 10-Q
AI-assisted comparison of EBS's 10-Q filed 2026-05-01 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- In newer filing (2026-05-01): Reference to Form 10-K for year ended December 31, 2025 (vs. 2024 in older filing)
- In newer filing (2026-05-01): Cross-reference to Q1 2025 10-Q filed May 8, 2025 for prior year comparison
- In newer filing (2026-05-01): NARCAN® described as 'Nasal Spray 4 mg' with specific OTC approval language
- In newer filing (2026-05-01): KLOXXADO® described as 'Nasal Spray 8 mg' with January 2025 agreement date stated
- In newer filing (2026-05-01): ANTHRASIL® capitalization change and trademark formatting
- In newer filing (2026-05-01): Share Repurchase Program section detailing March 2025 authorization, February 2026 reauthorization, and Q1 2026 repurchase activity ($9.1 million for 0.9 million shares)
- Removed:
- Removed from newer filing (2026-05-01): Four PHT categories description ('chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases (EID); emerging health crises; and acute, emergency and community care')
- Removed from newer filing (2026-05-01): NARCAN® product description without specific dosage (4 mg designation now added)
- Removed from newer filing (2026-05-01): KLOXXADO® product description without specific dosage and 'On January 14, 2025' date language
- Removed from newer filing (2026-05-01): Trobigard Revocation section (April 2, 2024 FAMHP market authorization revocation)
- Removed from newer filing (2026-05-01): Sale of RSDL® section (July 31, 2024 transaction with SERB Pharmaceuticals)
- Removed from newer filing (2026-05-01): May 2024 Organizational Restructuring Plan section header
- Reworded:
- NARCAN® product language changed from 'approved by the United States Food and Drug Administration (FDA) (including in over-the-counter (OTC) form)' to 'approved as an over-the-counter (OTC) medicine by the United States Food and Drug Administration (FDA)'
- Segment reporting reference changed from 'Note 17' in older filing to 'Note 15' in newer filing
- Services segment threshold language: 'did not meet the aggregation criteria' (older) changed to 'did not meet the aggregation criteria' with identical text but referenced as Note 15 vs. Note 17
- KLOXXADO agreement date specification: older filing states 'On January 14, 2025' while newer filing states 'In January 2025'
- Anthem product name capitalization: 'Anthrasil®' in older filing vs. 'ANTHRASIL®' in newer filing
- Notes:
- Newer filing text appears truncated at end of Share Repurchase Program section; full text not available for complete comparison
- Older filing text also truncated at 'May 2024 Organizational Restructuring Plan' section; comparison limited to available text
- Note references changed from 17 to 15, suggesting renumbering of financial statement notes between filings
Risk Factors
- Added:
- Added reference to 'KLOXXADO ® Nasal Spray' in the first bullet point regarding USG funding for MCM products (filed 2026-05-01)
- Added 'NOTE REGARDING TRADE NAMES' section listing trademarks and noting KLOXXADO ® is a registered trademark of Hikma Pharmaceuticals USA Inc. (filed 2026-05-01)
- Removed:
- Removed 'previously known as AV7909' descriptor for CYFENDUS ® (filed 2026-05-01)
- Removed reference to 'and KLOXXADO ® Nasal Spray' from NARCAN ® bullet point text (filed 2026-05-01)
- Removed bullet point regarding 'our ability to negotiate new or further commitments related to the collaboration and deployment of capacity toward future commercial manufacturing related to our bioservices and under existing Bioservices contracts' (filed 2026-05-01)
- Removed bullet point regarding 'our ability to realize the expected benefits of the sale of our travel health business to Bavarian Nordic, the sale of our Drug Product facility in Baltimore-Camden to Bora Pharmaceuticals Injectables Inc., a subsidiary of Bora Pharmaceuticals Co., Ltd. ("Bora"), the sale of RSDL ® (Reactive Skin Decontamination Lotion) to BTG International Inc., a subsidiary of SERB Pharmaceuticals (collectively, "SERB") and the sale of our Baltimore-Bayview drug substance manufacturing facility to Syngene International ("Syngene")' (filed 2026-05-01)
- Removed bullet point regarding 'our ability to realize the expected benefits from divestitures and restructuring activities' (filed 2026-05-01)
- Removed bullet point regarding 'our ability to realize the full benefits from our divestitures and sales of assets' (filed 2026-05-01)
- Removed 'as amended' from Private Securities Litigation Reform Act reference (filed 2026-05-01)
- Removed 'and divestitures' from restructuring initiatives phrase (filed 2026-05-01)
- Removed 'U.S.' abbreviation before 'Securities and Exchange Commission' reference (filed 2026-05-01)
- Removed sentence: 'In addition, other risks and uncertainties not presently known to us or that we currently believe to be immaterial could affect the accuracy of any forward-looking statements.' (filed 2026-05-01)
- Removed 'materially' from closing sentence before 'from our expectations in any forward-looking statement' (filed 2026-05-01)
- Reworded:
- Changed credit agreement reference from 'our term loan facility under a credit agreement, dated August 30, 2024, among the Company, the lenders from time to time party thereto and OHA Agency LLC, as administrative agent' to 'the Credit Agreement, dated April 16, 2026 (the "Term Loan Agreement"), by and among the Company, the lenders from time to time party thereto, and OrbiMed Royalty & Credit Opportunities V, LP, as administrative agent' (filed 2026-05-01)
- Changed 'the revolving credit facility under a credit agreement' to 'our revolving credit facility (the "Revolving Credit Facility") under a credit agreement' (filed 2026-05-01)
- Notes:
- The older filing text appears truncated at the end ('nor can it assess the impact of any such factor on the business or the extent to which any facto'), preventing complete verification of all differences in the final sentences
- Page number references changed from older filing pages (63-67) to newer filing pages (42-45), reflecting document restructuring
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 1 open-market sale by insiders in the last 90 days.
- Last 90 days0 buys · 1 sell ($25200) — 1 selling insider
- Last 180 days0 buys · 8 sells ($543440) — 5 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-01. As of 2026-08-25.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about EBS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for EBS from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding EBS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 8,129,298
- Reported value $67,473,170
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 1 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
EBS had 10,029,170 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
EBS had 19.6% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 17.65 days to cover at the same settlement.
- Reported short interest (shares) 10,029,170
- Short interest (% of shares outstanding) 19.6%
- Prior settlement (shares) 10,339,037
- Reported change -3%
- Days to cover (reported) 17.65
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Bavarian Nordic (BAVA.CO)
- Pfizer (PFE)
- Sanofi (SNY)
- GlaxoSmithKline (GSK)
- AstraZeneca (AZN)
- Catalent (CTLT)
- Thermo Fisher Scientific (TMO)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare EBS vs…
EBS ranks in…
Frequently asked questions
What does EMERGENT BIOSOLUTIONS INC (EBS) do?
Emergent BioSolutions is a global life sciences company that develops, manufactures, and delivers medical countermeasures and specialized pharmaceutical products to address public health threats. Its business is organized into three segments: Commercial Products (focused on opioid overdose reversal, including NARCAN Nasal Spray), Medical Countermeasure (MCM) Products (focused on vaccines and therapeutics for diseases like anthrax, smallpox, and Ebola), and a Services segment providing contract…
What sector is EMERGENT BIOSOLUTIONS INC (EBS) in?
EMERGENT BIOSOLUTIONS INC (EBS) is classified in the Health Care sector. Its industry is Biotechnology and CDMO Services. It trades on NYSE.
Who are EMERGENT BIOSOLUTIONS INC's (EBS) competitors?
Notable peers of EMERGENT BIOSOLUTIONS INC (EBS) include Bavarian Nordic, Pfizer, Sanofi, GlaxoSmithKline and AstraZeneca. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in EBS?
Yes — we hold 1 matched STOCK Act disclosure for EBS from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is EMERGENT BIOSOLUTIONS INC (EBS) overbought or oversold right now?
EMERGENT BIOSOLUTIONS INC (EBS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on EBS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-24.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.